NCT04509596
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor, Therapeutic Antibody, Chemotherapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with CNS complications that require urgent neurosurgical intervention
https://ClinicalTrials.gov/show/NCT04509596